Where Tech Meets Bio

Where Tech Meets Bio

Share this post

Where Tech Meets Bio
Where Tech Meets Bio
Absci and Other AI-Powered Biotechs Lead the Way in Antibody Discovery

Absci and Other AI-Powered Biotechs Lead the Way in Antibody Discovery

AI-driven drug discovery is traditionally associated with small molecules. Things are changing rapidly.

Andrii Buvailo's avatar
Andrii Buvailo
Apr 12, 2023
∙ Paid
6

Share this post

Where Tech Meets Bio
Where Tech Meets Bio
Absci and Other AI-Powered Biotechs Lead the Way in Antibody Discovery
1
Share
Image credit: Absci

The monoclonal antibody (mAb) market has seen impressive growth in recent years, with the top-selling drugs increasingly being mAbs. The success of these therapeutics has driven the pharma industry to seek innovative methods for refining and improving their antibody pipelines. Artificial intelligence (AI) and deep learning, which have…

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 BiopharmaTrend (BPT Analytics Ltd)
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share